Skip to content Skip to footer
Subscribe Now
Celltrion
NEWS

Celltrion’s Eydenzelt (Biosimilar, Eylea) Receives the US FDA’s Approval to Treat Multiple Retinal Diseases

Shots:The US FDA has approved Eydenzelt, a biosimilar version of Eylea (aflibercept), to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), & diabetic retinopathyApproval was supported by extensive analytical, non-clinical, & clinical data, incl. a P-III trial in DME pts (n=348) comparing Eydenzelt vs Eylea over…
October 10, 2025

Read more

Top Performing Drug of 2021 – Eylea (September Edition)
INSIGHTS+

Top Performing Drug of 2021 – Eylea (September Edition)

Active Ingredient: AfliberceptStrength: 2 mg (0.05 mL)Dosage Form: Injection (intravitreal)Mechanism of Action: VEGF-A and PlGF inhibitorsFirst Approval: US (18 Nov 2011), EU (27 Nov 2012)Revenue1EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…
September 22, 2022

Read more

PharmShots Interview In Conversation with Nancy Holekamp, Director of Retina Services, Where she Shares Insights on The Results of the Global Survey to Find the Impact of Geographic Atrophy
VIEWPOINTS

PharmShots Interview: In Conversation with Nancy Holekamp, Director of Retina Services, Where she Shares Insights on The Results of the Global Survey to Find the Impact of Geographic Atrophy

Shots:Nancy spoke about the results from the Geographic Atrophy Insights Survey (GAINS)Nancy also talked about the emotional burden on the patients and the devastating impact on independence caused by vision loss The global survey was conducted by The Harris Poll on behalf of Apellis Pharmaceuticals to find the impact of GA which is a…
July 6, 2022

Read more